title: Efficacy and Safety of Plasmakinetic Resection of the Prostate in Patients with a Prostate Gland Larger than 80 cc: 30-Month Follow-Up Results.
abstract: OBJECTIVE
  This study aimed to evaluate the efficacy and safety of transurethral plasmakinetic resection of the prostate (PKRP) for the treatment of patients with benign prostatic hyperplasia (BPH) in men with prostate volume >80 cc.
  
  
  METHODS
  From January 2010 to December 2011, 120 patients were included in our study; among these patients, 66 had prostate sizes of 80 cc to 100 cc and 54 had prostate sizes >100 cc. Pre-, peri- and postoperative evaluations were performed.
  
  
  RESULTS
  The mean operative duration of PKRP was 112 minutes, and the mean resected tissue weight was 60.01 g. Hemoglobin level decreased by 0.65±0.52 g/dL, and serum sodium content decreased by 0.06±2.62 mmol/L. The mean catheterization time was 83.05 hours, and the mean hospital stay was 12.47 days. The short follow-up time (30 months) demonstrated significant improvement in International Prostate Symptom Score, quality of life, and postvoid residual volume compared with preoperative characteristics. One patient underwent reoperation because of a blood clot in the bladder. Twelve patients complained of retrograde ejaculation. No patient experienced urinary incontinence.
  
  
  CONCLUSIONS
  PKRP is safe and efficacious for men with BPH who have a large prostate (volume >80 cc).
authors.affiliation: 1 Department of Urology, Zhongnan Hospital of Wuhan University , Wuhan, China .|2 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University , Wuhan, China .
authors.forename: Jing-Yu
authors.initials: JY
authors.lastname: Huang
authors.affiliation: 1 Department of Urology, Zhongnan Hospital of Wuhan University , Wuhan, China .|2 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University , Wuhan, China .
authors.forename: Sheng
authors.initials: S
authors.lastname: Li
authors.affiliation: 1 Department of Urology, Zhongnan Hospital of Wuhan University , Wuhan, China .
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Yang
authors.affiliation: 2 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University , Wuhan, China .
authors.forename: Xian-Tao
authors.initials: XT
authors.lastname: Zeng
authors.affiliation: 1 Department of Urology, Zhongnan Hospital of Wuhan University , Wuhan, China .|2 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University , Wuhan, China .
authors.forename: Xing-Huan
authors.initials: XH
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004598:Electrosurgery / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D061646:Operative Time; D009929:Organ Size; D011183:Postoperative Complications / Q000209:etiology; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000601:surgery*; D011788:Quality of Life; D012189:Retrospective Studies; D020728:Transurethral Resection of Prostate / Q000379:methods*